In vitro diagnostic (IVD) antibodies can provide important information for both diagnosis and treatment of different diseases. As one of the leading CRO companies in the IVD industry, Creative Biolabs is providing incomparable services for the development of high-quality antibodies with low cross-reactivity for the diagnosis of pancreatic cancers.
Introduction of TOP2A
Fig.1 Chalcone derivative CX258 suppresses colorectal
cancer by inhibiting the TOP2A/Wnt/β-catenin signaling.1 Mammalian cells contain two distinct types of topoisomerases, which are type I and type II enzyme. DNA topoisomerase 2-alpha (TOP2A) is encoded by the TOP2A gene. This enzyme controls and alters the topologic states of DNA during transcription. Moreover, it is involved in processes such as chromosome condensation, chromatid separation, and the relief of torsional stress that occurs during DNA transcription and replication. It catalyzes the transient breaking and rejoining of two strands of duplex DNA which allows the strands to pass through one another, thus altering the topology of DNA. Studies have reported that TOP2A could induce tumor development and progression in many cancer types, such as prostate cancer, breast cancer, pancreatic cancer, and hepatocellular carcinoma.
TOP2A Marker for Pancreatic Cancer
Pancreatic cancer continues to have one of the highest mortality rates of any malignancy because the vast majority of patients are diagnosed at an advanced stage of the disease. Thus, new tumor markers of pancreatic cancer are urgently needed for reliable screening for pancreatic cancer at an early, potentially curative stage. TOP2A is such a potential tumor biomarker for early diagnosis of pancreatic cancers. It is a target for several chemotherapeutic agents, including doxorubicin, that has been used for the treatment of advanced pancreatic cancer. A variety of mutations in TOP2A have been associated with drug resistance. Moreover, Pei et al. (2017) reported that TOP2A was up-regulated in pancreatic cancer as compared with non-tumor tissues. Moreover, the up-regulation of TOP2A was significantly correlated with tumor metastasis and shorter survival in patients with pancreatic cancer. Knockdown of TOP2A in pancreatic cancer cell lines inhibited cell proliferation and migration. Furthermore, bioinformatics analysis revealed TOP2A activatesβ-catenin pathway in pancreatic cancer.
IVD Antibody Development Services Targeting TOP2A Marker
Immunoassays based on antigen-antibody immunological response play an important role in the diagnosis and differential diagnosis of diseases of the tumors. We tailor services to develop high-quality IVD antibodies against a variety of widely used tumor markers (e.g., TOP2A) of pancreatic cancers for the development of different immunoassay formats, including ELISA, lateral flow, electrochemiluminescence, and immunohistochemistry, to meet the needs of our valued IVD clients. With our versatile IVD platform, Creative Biolabs is proud to develop novel TOP2A-specific (paired) antibodies from scratch to commercial IVD kit (we can also start with provided antibody candidates).
Creative Biolabs is one of the world-leading service providers for the IVD antibodies development. We are pleased to use our extensive experience and advanced platform to offer the best IVD antibodies against various biomarkers for different kinds of cancers. Contact us to discuss your specific requirements and experience the great value of our expert services.
Reference
For Research Use Only.
